OM:CIBUS
OM:CIBUSReal Estate

How Cibus Nordic’s New €85m 2030 Green Bond and Early Redemption Will Impact Cibus Nordic Real Estate (OM:CIBUS) Investors

Cibus Nordic Real Estate AB (publ) has completed a refinancing move, issuing €85 million of new floating rate senior unsecured green notes due 2030 and confirming the unconditional early redemption of its initial €50 million green notes at 101.25% plus accrued interest, with settlement on 4 February 2026. This refinancing reshapes Cibus’ debt profile by replacing an earlier green bond with a larger, longer-dated issue, potentially enhancing financial flexibility and reinforcing its...
OM:ALFA
OM:ALFAMachinery

Alfa Laval’s Gulf Coast Service Bet Raises Fresh Questions About Its Competitive Edge (OM:ALFA)

Alfa Laval has expanded its La Porte Service Center on the U.S. Gulf Coast into a 5,000-square-foot hub for large-scale Welded Heat Exchanger service, featuring increased hook height and two 25-ton cranes to improve efficiency for energy, chemical, and process customers. The facility’s focus on advanced service capabilities and integrated sustainability measures highlights how Alfa Laval is aligning industrial support with environmental performance goals in a key U.S. region. We’ll now...
OM:EKTA B
OM:EKTA BMedical Equipment

Elekta (OM:EKTA B) Valuation Check After FDA Clearance For Evo CT Linac Entry Into US Market

Elekta (OM:EKTA B) has attracted fresh attention after its Elekta Evo CT-Linac received FDA 510(k) clearance, opening the door for U.S. adoption of its AI supported imaging and radiation therapy platform. See our latest analysis for Elekta. The FDA clearance arrives at a time when Elekta’s share price has a 90 day share price return of 20.20% and a 30 day share price return of 6.47%, while the 1 year total shareholder return of a 2.89% decline and 5 year total shareholder return of a 40%...
OM:EMBRAC B
OM:EMBRAC BEntertainment

Embracer Group (OM:EMBRAC B) Valuation Check As Lee Guinchard Steps Up As Chief Operating Officer

Embracer Group (OM:EMBRAC B) has appointed long time games and entertainment executive Lee Guinchard as Chief Operating Officer, expanding his remit as the company reshapes itself into Fellowship Entertainment and refines how it uses key franchises. See our latest analysis for Embracer Group. Guinchard’s appointment comes after a difficult period for investors, with the share price at SEK 49.21 and a 90 day share price return showing a 52.24% decline, while the 1 year total shareholder return...
OM:SHOT
OM:SHOTHospitality

Is Scandic Hotels Group’s (OM:SHOT) Tromsø Mixed-Use Lease a Template for Capital-Light Expansion?

Scandic Hotels Group has announced plans to open a second Scandic Go hotel in Norway, a 170-room property in a new mixed-use building in central Tromsø under a long-term lease with Nordlyskvartalet AS, with construction scheduled to start after summer 2026 and opening expected in 2028. This project will make Tromsø the first non-capital city to host all three of Scandic’s brands and further embeds the company’s Nordicwan Ecolabel-focused approach to hotel operations, including the use of...
OM:IDLDX
OM:IDLDXLife Sciences

European Penny Stocks To Watch: 3 Picks With Market Caps Over €30M

The European market has shown resilience, with the STOXX Europe 600 Index gaining ground thanks to robust economic data and encouraging earnings results. Amid this backdrop, penny stocks—though often associated with speculative trading—remain a relevant investment area when backed by solid financials. These smaller or newer companies can offer a unique blend of affordability and growth potential, making them attractive options for investors seeking opportunities beyond the mainstream.
OM:CAMX
OM:CAMXPharmaceuticals

How FDA Review of Oclaiz Could Shape Camurus’ (OM:CAMX) Long-Term Endocrinology Strategy

Camurus AB (publ) recently announced that the U.S. FDA has accepted for review its resubmitted New Drug Application for Oclaiz (CAM2029), an extended-release octreotide injection for acromegaly, with a PDUFA target action date set for 10 June 2026. This acceptance helps clear a prior hurdle tied to third-party manufacturing observations and follows earlier EU and UK approvals and launch of the same product, marketed there as Oczyesa. We will now examine how FDA acceptance of the Oclaiz...